Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors

Tenatumomab is an anti-tenascin murine monoclonal antibody previously used in clinical trials for delivering radionuclides to tumors by both pre-targeting (biotinylated Tenatumomab within PAGRIT) and direct 131Iodine labeling approaches. Here we present the synthesis and in vitro characterization of three Tenatumomab con-jugates to bifunctional chelating agents (NHS-DOTA, NCS-DOTA and NCS-DTPA). Results indicate ST8198AA1(Tenatumomab-DOTAMA, derived by conjugation of NHS-DOTA), as the most promising candidate in terms ofconjugation rate andyield, stability,antigenimmunoreactivity andaffinity. Labeling efficiency of thedifferentchelators was investigated with a panel of cold metals indicating DOTAMA as the best chelator. Labeling ofTenatumomab-DOTAMA was then optimized with several metals and stability performed confirms suitability of this conjugate for further development. ST8198AA1 represents an improvement of the previous antibody forms because the labeling with radionuclides like177Lu or64Cu would allow theranostic applications in patientsbearing tenascin expressing tumors